Co-Authors
This is a "connection" page, showing publications co-authored by Stefano Piaserico and Paolo Gisondi.
Connection Strength
4.617
-
Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments. J Eur Acad Dermatol Venereol. 2021 Jun; 35(6):e361-e362.
Score: 0.934
-
Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. J Invest Dermatol. 2022 02; 142(2):355-363.e7.
Score: 0.240
-
Impact of the COVID-19 pandemic on melanoma diagnosis. J Eur Acad Dermatol Venereol. 2021 Nov; 35(11):e714-e715.
Score: 0.240
-
Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. Dermatol Ther (Heidelb). 2021 Aug; 11(4):1333-1343.
Score: 0.238
-
Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. Dermatol Ther (Heidelb). 2021 Jun; 11(3):695-705.
Score: 0.234
-
Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy? J Eur Acad Dermatol Venereol. 2021 Jun; 35(6):e355-e357.
Score: 0.233
-
The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol. 2021 Sep-Oct; 39(5):1099-1107.
Score: 0.232
-
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2021 Feb; 147(2):558-560.e1.
Score: 0.228
-
Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020 10; 21(5):749-751.
Score: 0.226
-
Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020 Nov; 34(11):2499-2504.
Score: 0.223
-
Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020 Jun; 34(6):1196-1201.
Score: 0.221
-
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020 08; 183(2):373-374.
Score: 0.221
-
Consensus on the management of patients with psoriatic arthritis in a dermatology setting. J Eur Acad Dermatol Venereol. 2018 Apr; 32(4):515-528.
Score: 0.187
-
Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. Br J Dermatol. 2017 12; 177(6):e325-e326.
Score: 0.186
-
How to improve adherence to treatment in patients with mild-to-moderate psoriasis. G Ital Dermatol Venereol. 2018 Oct; 153(5):692-697.
Score: 0.181
-
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 May; 31(5):774-790.
Score: 0.177
-
Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017 Nov; 31(11):1853-1859.
Score: 0.176
-
Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013 May; 168(5):1124-7.
Score: 0.135
-
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opin Biol Ther. 2021 02; 21(2):271-277.
Score: 0.058
-
Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatol Ther. 2017 Sep; 30(5).
Score: 0.045